nasopharyngitis


Also found in: Dictionary, Thesaurus, Encyclopedia.

nasopharyngitis

 [na″zo-far″in-ji´tis]
inflammation of the nasopharynx.

nasopharyngitis

/na·so·phar·yn·gi·tis/ (-far″in-ji´tis) inflammation of the nasopharynx.

nasopharyngitis

Infectious disease Acute nasopharyngeal inflammation, often with keratoconjunctivitis; both occur in common cold and are attributed to viruses. see Common cold.

nasopharyngitis

inflammation of the nasopharynx.
References in periodicals archive ?
This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Subjects were patients seen in an ambulatory setting for the common cold, defined as acute nasopharyngitis.
Global Markets Direct's, 'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2012', provides an overview of the Nasopharyngitis (Common Cold) therapeutic pipeline.
The most common adverse events observed occurring in greater than 3% of patients on Xeljanz 5 mg BID were nasopharyngitis, upper respiratory tract infection, headache and diarrhea.
These included nasopharyngitis (9% of both groups), upper respiratory tract infection (6%), injection site reaction (4%), headache (3%), and worsening of psoriasis (1% for CHS-1420, and 3% for adalimumab).
The most commonly reported adverse events reported during trials, occurring at a rate equal to or greater than 5%, were headache (21%), fatigue (17%), nasopharyngitis (8%), pruritus (8%), nausea (6%) and asthenia (5%).
USPRwire, Fri Jan 23 2015] Global Markets Direct's, 'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2014', provides an overview of the Nasopharyngitis (Common Cold)'s therapeutic pipeline.
ClickPress, Fri Jan 17 2014] GlobalData's clinical trial report, "Nasopharyngitis (Common Cold) Global Clinical Trials Review, H2, 2013" provides data on the Nasopharyngitis (Common Cold) clinical trial scenario.
Overall, 63 of the XR-NTX patients (50%) and 40 of the placebo patients (32%) experienced at least one adverse event, the most common of which were nasopharyngitis and insomnia.
The most frequent AEs were nasopharyngitis (52%), headache (19%), blood alkaline phosphatase increases (19%) and anemia (11%).
Overall, Symbicort was well tolerated, with nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and viral upper respiratory tract infections the most commonly reported drug-related adverse events, according to the product label.
Adverse events were dizziness (37%), which was transient and usually ceased as patients adjusted to the medication; headache (18%), fatigue, and nasopharyngitis (14% each); and diplopia, abnormal vision, and upper respiratory tract infection (13% each).